Direct Global Manufacturer Sourcing
Connect directly with verified manufacturers globally. Post your licensing requirements and get feedback from multiple qualified manufacturers without intermediary friction or zero brokerage fees.
The AI-powered B2B partnering hub for Pharmaceutical Executives. Connect directly with verified manufacturers globally across Innovative assets, Biosimilars, Value Added Products (VAPs), and Generics.
Atorvastatin 20mg FC Tab
Cardiovascular · Rx · Generic
Dexketoprofen Sachet
Pain / OTC switch · OTC
Semaglutide Analog (Pre-IND)
Metabolic · Rx · Innovative
Core value
Every capability is built around confidential evaluation, anonymous portfolio presentation, and mutual-interest dealmaking.
Connect directly with verified manufacturers globally. Post your licensing requirements and get feedback from multiple qualified manufacturers without intermediary friction or zero brokerage fees.
Make smarter portfolio decisions using our AI-powered research engines. Gain visibility into upcoming trends and monitor competitive activity across international markets in real time.
Seamlessly source and license Innovative pharmaceuticals, Biosimilars, Value Added Products (VAPs), and Generics across commercial and clinical pipeline stages.
Accelerate portfolio development and expand your partner network efficiently ahead of major industry events like CPhI Milan 2026.
Register before CPhI 2026 in Milan to expand your partner network efficiently and make smarter portfolio decisions with 1 Year Free Access (Reg. €249/year). Standard membership will cost €249/year after our official CPhI launch.
We respect your privacy. Unsubscribe at any time. See our Privacy Policy for details.
Pharma Marketplace
Filter by therapeutic area, dosage form, regulatory status, dossier type and target territory. Each listing carries the technical and commercial data your evaluation committee needs before the first call.
Solutions
Browse anonymous product listings from early clinical phases to commercial assets. Filter by target markets and send confidential contact requests directly to offering parties.
Publish your portfolio 100% anonymously. Define specific market availabilities and stay in full control—your identity is revealed only when you accept a contact request.
Cut out cold outreach and spam. Engage only with genuinely interested counterparties through mutual-interest matchmaking and instant platform chat.
How it works
Pharmaceutical licensing is often slowed down by privacy concerns and unsolicited outreach. 1IBHub solves this by keeping all product listings strictly anonymous until mutual interest is confirmed, compressing months of searching into four simple steps.
Publish Rx, OTC, clinical, or commercial assets completely anonymously. Specify therapeutic areas, dosage forms, and select target markets where your product is available—keeping your company identity protected.
In-licensing managers filter anonymous product listings by therapeutic area, development phase, formulation, and target territory to find exact portfolio fits in minutes without revealing their strategic focus to competitors.
Submit a contact request on an anonymous listing or get matched based on aligned supply/demand criteria. Following a double opt-in principle, no contact details or company names are revealed unless the offering party accepts.
Once the contact request is accepted by the seller, both parties are connected on the platform. Open a secure, direct chat thread to exchange dossier details, negotiate term sheets, and advance cross-border deals.
FAQ
The questions licensing teams ask us most often about in-licensing, out-licensing, and building a pharmaceutical partnering pipeline on 1IBHub.
Share 1IBHub with your BD network
Register before CPhI 2026 in Milan to expand your partner network efficiently and make smarter portfolio decisions with 1 Year Free Access (Reg. €249/year). Standard membership will cost €249/year after our official CPhI launch.
We respect your privacy. Unsubscribe at any time. See our Privacy Policy for details.
Have questions regarding B2B licensing or early platform access? Send us a direct message.